Peptide Comparison
Intermedin (Adrenomedullin-2)vsBPC-157
A powerful peptide hormone that protects your heart and blood vessels while managing stress and inflammation naturally.
The "Wolverine peptide" known for its remarkable healing properties across tendons, ligaments, muscles, and the gut.
At a Glance
Quick
comparison
Dose Range
Intermedin (Adrenomedullin-2)
As prescribed–As prescribed mg
BPC-157
250–500 mcg
Frequency
Intermedin (Adrenomedullin-2)
Once daily
BPC-157
Once daily
Administration
Intermedin (Adrenomedullin-2)
As directed by healthcare provider
BPC-157
Subcutaneous injection
Cycle Length
Intermedin (Adrenomedullin-2)
Ongoing/indefinite
BPC-157
4-6 weeks
Onset Speed
Intermedin (Adrenomedullin-2)
Moderate (1-2 weeks)
BPC-157
Moderate (1-2 weeks)
Evidence Level
Intermedin (Adrenomedullin-2)
Limited human trials
BPC-157
Strong preclinical (extensive animal studies)
Efficacy
Benefit
ratings
Cardiovascular Health & Protection
Stress & Anxiety Management
Anti-Inflammatory & Antioxidant Support
Primary Benefit
Secondary Benefit
Additional Benefit
Technical Data
Compound
specifications
Intermedin (Adrenomedullin-2)
Molecular Formula
C15H25NO5 (precursor compound)
Molecular Weight
299.36 g/mol (precursor)
Half-Life
Approximately 2-6 hours (varies by route of administration)
Bioavailability
Varies by route of administration
CAS Number
148498-78-6
BPC-157
Molecular Formula
C62H98N16O22
Molecular Weight
1419.53 g/mol
Half-Life
4-6 hours
Bioavailability
~100% (subcutaneous)
CAS Number
137525-51-0
Protocols
Dosing
tiers
Intermedin (Adrenomedullin-2)
BPC-157
Applications
Best
suited for
Intermedin (Adrenomedullin-2)
Supporting cardiovascular health and heart function
Intermedin (Adrenomedullin-2) is particularly well-suited for individuals focused on supporting cardiovascular health and heart function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Managing inflammation and oxidative stress
Intermedin (Adrenomedullin-2) is particularly well-suited for individuals focused on managing inflammation and oxidative stress. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Improving overall vascular health and circulation
Intermedin (Adrenomedullin-2) is particularly well-suited for individuals focused on improving overall vascular health and circulation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
BPC-157
Tendon and ligament injuries
Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair
Gut healing
IBS, leaky gut, ulcers, inflammatory bowel conditions - derived from gastric juice, it has a natural affinity for digestive tissue
Muscle injuries
Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression
Joint problems
Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties
Post-surgical recovery
Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms
Safety Profile
Side
effects
Intermedin (Adrenomedullin-2)
Common
- Mild discomfort at treatment site
- Flushing and mild facial redness
- Dizziness or lightheadedness
- Mild headache
- Injection site reactions (redness, itching, swelling)
- Nausea or mild gastrointestinal discomfort
- Fatigue or mild energy changes
- Transient hypotension (temporary low blood pressure)
- Mild palpitations (in some individuals)
Serious
- Severe allergic reaction
BPC-157
Common
- Injection site redness
- Mild nausea
- Dizziness
Uncommon
- Headache
- Fatigue
- Hot/cold sensations
Serious
- Allergic reaction
Research Status
Safety
& evidence
Intermedin (Adrenomedullin-2)
Evidence Level
Limited human trials
FDA Status
Not FDA approved
Safety Overview
Intermedin (Adrenomedullin-2) is an endogenous peptide hormone with systemic vascular and renal effects that warrant cautious use. As a vasodilator acting through CGRP and other peptide receptors, it can significantly lower blood pressure—a key safety consideration for hypotensive or cardiovascular-compromised individuals. Preclinical studies show dose-dependent hypotensive effects and tachycardia, limiting clinical translation. The compound remains largely experimental with limited safety data in humans outside specific research contexts.
Contraindications
- xPregnancy and breastfeeding - insufficient safety data
- xActive cardiovascular events (heart attack, stroke)
- xSevere renal (kidney) impairment
- xHypersensitivity to calcitonin family peptides
- xUncontrolled endocrine disorders
BPC-157
Evidence Level
Strong preclinical (extensive animal studies)
FDA Status
Research compound
Safety Overview
BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. No FDA approval exists. Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.
Contraindications
- xPregnancy
- xBreastfeeding
- xActive cancer
- xHistory of cancer
Decision Guide
Which is
right for you?
Choose Intermedin (Adrenomedullin-2) if...
- Supporting cardiovascular health and heart function
- Managing inflammation and oxidative stress
- Improving overall vascular health and circulation
Choose BPC-157 if...
- Injury recovery
- Post-surgery healing
- Chronic pain management
- Gut health